Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children

HIV Medicine

Volumn 13, Issue 5, 2012, Pages 264-275

  Miller, T L ^a   Borkowsky, W ^b   Dimeglio, L A ^c   Dooley, L ^d   Geffner, M E ^e   Hazra, R ^f   McFarland, E J ^g   Mendez, A J ^a   Patel, K ^h   Siberry, G K ^f   Van Dyke, R B ⁱ   Worrell, C J ^f   Jacobson, D L ^h  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

ⁱ TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Biomarkers; Cardiovascular risk factors; Children; HIV AIDS; Vascular dysfunction

Indexed keywords

ABACAVIR; ADIPONECTIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; INSULIN; INTERLEUKIN 6; LIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PROTEINASE INHIBITOR; STAVUDINE; VASCULAR CELL ADHESION MOLECULE 1;

ADOLESCENT; ANTHROPOMETRY; ARTICLE; BLOOD CLOTTING DISORDER; BODY COMPOSITION; BODY FAT; BODY MASS; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; PRENATAL EXPOSURE; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SCORING SYSTEM; VASCULAR DISEASE; VIRUS REPLICATION; WAIST HIP RATIO;

ADOLESCENT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CELL ADHESION MOLECULES; CHEMOKINE CCL2; CHILD; COHORT STUDIES; E-SELECTIN; FEMALE; FIBRINOGEN; HIV INFECTIONS; HIV-1; HUMANS; HYPERLIPIDEMIAS; INTERLEUKIN-6; MALE; MULTIVARIATE ANALYSIS; P-SELECTIN; RISK FACTORS; VIRUS REPLICATION;

EID: 84859421400     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00970.x     Document Type: Article

References (58)

1. Laufer M, Scott GB. Medical management of HIV disease in children. Pediatr Clin North Am 2000; 47: 127-153.
2. Grinspoon SK, Grunfeld C, Kotler DP etal. State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 2008; 118: 198-210.
3. Arpadi SM, Bethel J, Horlick M etal. Longitudinal changes in regional fat content in HIV-infected children and adolescents. AIDS 2009; 23: 1501-1509.
4. Bitnun A, Sochett E, Dick PT etal. Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naive human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2005; 90: 168-174.
5. Miller TL, Grant YT, Almeida DN, Sharma T, Lipshultz SE. Cardiometabolic disease in human immunodeficiency virus-infected children. J Cardiometab Syndr 2008; 3: 98-105.
6. Miller TL, Orav EJ, Lipshultz SE etal. Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. J Pediatr 2008; 153: 491-497.
7. Sanchez Torres AM, Munoz Muniz R, Madero R, Borque C, Garcia-Miguel MJ, De Jose Gomez MI. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr 2005; 164: 271-276.
8. Reiss AB. Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus. Curr Rheumatol Rep 2009; 11: 255-260.
9. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010; 53: 1270-1287.
10. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-2138.
11. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008; 54: 24-38.
12. Friis-Moller N, Sabin CA, Weber R etal. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
13. Friis-Moller N, Reiss P, Sabin CA etal. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735.
14. Pace GW, Leaf CD. The role of oxidative stress in HIV disease. Free Radic Biol Med 1995; 19: 523-528.
15. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51: 268-273.
16. McGill HC Jr, McMahan CA, Gidding SS. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Circulation 2008; 117: 1216-1227.
17. Pencina MJ, D'Agostino RB Sr, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the Framingham heart study. Circulation 2009; 119: 3078-3084.
18. de Ferranti SD, Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol 2007; 16: 14-21.
19. Bonaterra GA, Zugel S, Kinscherf R. Novel systemic cardiovascular disease biomarkers. Curr Mol Med 2010; 10: 180-205.
20. Baker JV, Duprez D. Biomarkers and HIV-associated cardiovascular disease. Curr Opin HIV AIDS 2010; 5: 511-516.
21. Worm SW, Hsue P. Role of biomarkers in predicting CVD risk in the setting of HIV infection? Curr Opin HIV AIDS 2010; 5: 467-472.
22. Miller TL, Somarriba G, Orav EJ etal. Biomarkers of vascular dysfunction in children infected with human immunodeficiency virus-1. J Acquir Immune Defic Syndr 2010; 55: 182-188.
23. Hickman TB, Briefel RR, Carroll MD etal. Distributions and trends of serum lipid levels among United States children and adolescents ages 4-19 years: data from the Third National Health and Nutrition Examination Survey. Prev Med 1998; 27: 879-890.
24. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM etal. CDC growth charts: United States. Adv Data 2000; 8: 1-27.
25. National health and nutrition examination survey III body measurements (anthropometry). 2010. Available at (accessed 1 December 2010).
26. Margulies L, Horlick M, Thornton JC, Wang J, Ioannidou E, Heymsfield SB. Reproducibility of pediatric whole body bone and body composition measures by dual-energy X-ray absorptiometry using the GE Lunar Prodigy. J Clin Densitom 2005; 8: 298-304.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
28. Caldwell MB, Oxtoby MJ, Simonds RJ, Lindegren ML, Rogers MF. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR CDC Surveill Summ 1994; 43: 1-10.
29. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
30. Thomas NE, Baker JS, Graham MR, Cooper SM, Davies B. C-reactive protein in schoolchildren and its relation to adiposity, physical activity, aerobic fitness and habitual diet. Br J Sports Med 2008; 42: 357-360.
31. Kuller LH, Tracy R, Belloso W etal. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
32. Neuhaus J, Jacobs DR Jr, Baker JV etal. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201: 1788-1795.
33. Ford ES, Greenwald JH, Richterman AG etal. Traditional risk factors and d-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010; 24: 1509-1517.
34. Choudhury RP, Rong JX, Trogan E etal. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler Thromb Vasc Biol 2004; 24: 1904-1909.
35. Cockerill GW, Huehns TY, Weerasinghe A etal. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001; 103: 108-112.
36. Ashby DT, Rye KA, Clay MA, Vadas MA, Gamble JR, Barter PJ. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18: 1450-1455.
37. Dichtl W, Nilsson L, Goncalves I etal. Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. Circ Res 1999; 84: 1085-1094.
38. Ting HJ, Stice JP, Schaff UY etal. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha. Circ Res 2007; 100: 381-390.
39. Madden E, Lee G, Kotler DP etal. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS 2008; 22: 707-715.
40. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185: 456-462.
41. de Larranaga GF, Bocassi AR, Puga LM, Alonso BS, Benetucci JA. Endothelial markers and HIV infection in the era of highly active antiretroviral treatment. Thromb Res 2003; 110: 93-98.
42. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-1801.
43. Ross AC, Rizk N, O'Riordan MA etal. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009; 49: 1119-1127.
44. Gaddi E, Laucella S, Balbaryski J etal. Prognostic value of soluble intercellular adhesion molecule-1 (s-ICAM-1) in HIV-infected children. Scand J Immunol 2000; 52: 628-633.
45. Vicenzi E, Alfano M, Ghezzi S etal. Divergent regulation of HIV-1 replication in PBMC of infected individuals by CC chemokines: suppression by RANTES, MIP-1alpha, and MCP-3, and enhancement by MCP-1. J Leukoc Biol 2000; 68: 405-412.
46. Calmy A, Gayet-Ageron A, Montecucco F etal. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009; 23: 929-939.
47. Jiang B, Hebert VY, Li Y, Mathis JM, Alexander JS, Dugas TR. HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. Toxicol Appl Pharmacol 2007; 224: 60-71.
48. Zhong DS, Lu XH, Conklin BS etal. HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol 2002; 22: 1560-1566.
49. Chen C, Lu XH, Yan S, Chai H, Yao Q. HIV protease inhibitor ritonavir increases endothelial monolayer permeability. Biochem Biophys Res Commun 2005; 335: 874-882.
50. Mondal D, Pradhan L, Ali M, Agrawal KC. HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. Cardiovasc Toxicol 2004; 4: 287-302.
51. Ross AC, Storer N, O'Riordan MA, Dogra V, McComsey GA. Longitudinal changes in carotid intima-media thickness and cardiovascular risk factors in human immunodeficiency virus-infected children and young adults compared with healthy controls. Pediatr Infect Dis J 2010; 29: 634-638.
52. Charakida M, Loukogeorgakis SP, Okorie MI etal. Increased arterial stiffness in HIV-infected children: risk factors and antiretroviral therapy. Antivir Ther 2009; 14: 1075-1079.
53. Bonnet D, Aggoun Y, Szezepanski I, Bellal N, Blanche S. Arterial stiffness and endothelial dysfunction in HIV-infected children. AIDS 2004; 18: 1037-1041.
54. Charakida M, Donald AE, Green H etal. Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation 2005; 112: 103-109.
55. McComsey GA, O'Riordan M, Hazen SL etal. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS 2007; 21: 921-927.
56. Ross AC, O'Riordan MA, Storer N, Dogra V, McComsey GA. Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children. Atherosclerosis 2010; 211: 492-498.
57. Perez-Atayde AR, Kearney DI, Bricker JT etal. Cardiac, aortic, and pulmonary arteriopathy in HIV-infected children: the Prospective P2C2 HIV Multicenter Study. Pediatr Dev Pathol 2004; 7: 61-70.
58. Castro C, Tracy RP, Deckelbaum RJ, Basch CE, Shea S. Adiposity is associated with endothelial activation in healthy 2-3 year-old children. J Pediatr Endocrinol Metab 2009; 22: 905-914.